Paul Atkins, nominated by Trump, has been sworn in as SEC chair

Protego Biopharma

company

About

Protego Biopharma develops therapeutics based on the clear human genetic link, excellent human safety profile, proof-of-principle efficacy.

  • San Diego,California,United States
  • 1 - 10

Details

Last Funding Type
Series A
Last Funding Money Raised
$51.04M
Industries
Biopharma,Biotechnology,Medical,Therapeutics
Founded date
Jan 1, 2011
Number Of Employee
1 - 10
Operating Status
Active
Also Known As
Misfolding Diagnostics, Inc.

Protego Biopharma develops therapeutics based on the clear human genetic link, excellent human safety profile, proof-of-principle efficacy. The company was founded in 2011 and is headquartered in San Diego, California.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$51.04M
Protego Biopharma has raised a total of $51.04M in funding over 2 rounds. Their latest funding was raised on Oct 19, 2021 from a Series A round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Oct 19, 2021 Series A $51.04M 3 Lightspeed Venture Partners
MPM Capital
Vida Ventures
Detail

Investors

Number of Lead Investors
Number of Investors
3
3
Protego Biopharma is funded by 3 investors. Lightspeed Venture Partners and MPM Capital are the most recent investors.
Investor Name Lead Investor Funding Round
Lightspeed Venture Partners Yes Series A
MPM Capital Yes Series A
Vida Ventures Yes Series A

Employee Profiles

Number of Employee Profiles
4
Protego Biopharma has 4 current employee profiles, including Board member Shelley Chu
Board member
Board member
Board member